anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R=-C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1.alpha. and HIF-2.alpha. proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-.kappa.B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia¨reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
Rales and moist breath sounds can occur transiently after administration. Endotracheal suctioning or other remedial action is not necessary unless clear-cut signs of airway obstruction are present. 

Increased probability of post-treatment nosocomial sepsis in SURVANTA-treated infants was observed in the controlled clinical trials (Table 3). The increased risk for sepsis among SURVANTA-treated infants was not associated with increased mortality among these infants. The causative organisms were similar in treated and control infants. There was no significant difference between groups in the rate of post-treatment infections other than sepsis. 

Use of SURVANTA in infants less than 600 g birth weight or greater than 1750 g birth weight has not been evaluated in controlled trials. There is no controlled experience with use of SURVANTA in conjunction with experimental therapies for RDS (eg, high-frequency ventilation or extracorporeal membrane oxygenation). 

No information is available on the effects of doses other than 100 mg phospholipids/kg, more than four doses, dosing more frequently than every 6 hours, or administration after 48 hours of age.
The invention relates to an application of a composition of red sage root and astragalus root components and a preparation thereof in synergy with a PD-1 inhibitor to resist liver cancer. The composition of the components of the red sage root and the astragalus root is a composition of the active component of the red sage root, tanshinone IIA and the active component of the astragalus root, astragaloside IV. The active ingredient composition has the function of improving the anti-tumor curative effect by cooperating with the PD-1 inhibitor. In addition, the medicine can be cooperated with a pharmaceutically acceptable carrier to realize in-vivo medicine delivery in the form of a preparation, and the carrier can be MOF, microemulsion and the like to co-carry insoluble components of tanshinone IIA and astragaloside IV. Both vectors can obviously improve the solubility and bioavailability of tanshinone IIA and astragaloside IV, and can be targeted to tumor tissues passively by EPR effect or actively by membrane modification. The MOF carrier has the advantage of high drug loading, and the microemulsion carrier has simple preparation process and is beneficial to industrial production. The two can be respectively combined with the PD-1 inhibitor to obviously improve the anti-tumor curative effect of the PD-1 inhibitor.
G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
The present invention provides a heath-care medicine for treating hypertension. The technical problem to be settled by the invention is to provide a pure Chinese medicine preparation which has the advantages of treating effect that is more stable than the treating effect of prior western medicine, high reliability, short treating period, no toxic or side effect. The invention confects the preparation with traditional Chinese medicinal herbs and accords with the theory of traditional Chinese medical science. The preparation of the invention selects the following Chinese medicinal herbs: magnet, frank incense, prunella spike, pseudo-ginseng, whitethorn, codonopsis pilosula, kendir, coptis, Chinese aloe, amber, bitter almond, radix bupleuri, dried giner, bighead atractylodes rhizome, medicinal cyathula root, yam, amomum villosum, pinellia tuber, rhizome of bornet cowlily, gastrodia elata, dried rehmannia root, pawpaw, penoy, groomwell root, thallus laminariae, saussurea involucrate and root-bank of spine data. The medicine has excellent treating effect for hypertension people in each age bracket, and has health-care function for people. Therefore the generation has excellent social benefit and economic benefit.
Synthetic amyloid enhancing compositions for inducing amyloidosis in a subject are described. Methods are described for using synthetic amyloid enhancing compositions to induce a subject to have increased amyloid deposition. Methods for administering to a subject an effective amount of a synthetic amyloid enhancing composition in conjunction with inflammatory stimulus to induce amyloidosis are provided. Compositions for inducing amyloidosis in a subject are described. The composition includes an effective amount of a synthetic amyloid enhancing composition in a pharmaceutically acceptable carrier. Other aspects describe packaged synthetic amyloid enhancing compositions for inducing amyloidosis.
INTRODUCTION: Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental Q8 conditions characterized by deficits in social interaction/communication and restrictive/repetitive behaviors. Recent studies highlight the role of immune system dysfunction and inflammation in ASD pathophysiology. Indeed, elevated levels of pro-inflammatory cytokines were described in the brain and peripheral blood of ASD individuals. Despite this, how this pro-inflammatory profile evolves with aging and whether it may be associated with behavioral deficits is unknown. In this work, we explored the impact of aging on motor behavior and inflammation using Shank3b mutant mice, a model for syndromic ASD.
METHODS: Using RT-qPCR and flow cytometry, we examined the expression of key pro-inflammatory molecules in the cerebellum, bone marrow, spleen, and peripheral blood, comparing adult and old Shank3b +/+, Shank3b +/-, and Shank3b -/- mice.
RESULTS AND DISCUSSION: Our findings revealed genotype- and age-related differences in inflammation and motor behavior, with Shank3b-/- mice exhibiting accelerated aging and motor impairments. Correlations between pro-inflammatory molecules and behavioral deficits suggest that a link may be present between systemic inflammation and ASD-related behaviors, underscoring the potential role of age-related inflammation ("inflammaging") in exacerbating ASD symptoms.
A method, an apparatus, and a system for exchanging medical information. A portable computing device uniquely associated with a user may communicate the medical information to a healthcare provider. The medical information may be combined with other information and electronically delivered to the healthcare provider. Delivery may be initiated by the portable computing device and directed to a computing device of a healthcare provider or patient. In one example, exchange of records and other information between the user and the provider can be effected using an optical code to transmit encrypted, coded medical information together with cryptographic keys necessary to extract the coded medical information. The coded medical information may be automatically remapped and/or translated according to a state, country, region and/or language associated with the healthcare provider or patient.
PURPOSE:To obtain a contrasting agent composition having decreased viscosity of viscous iodinated oil and improved handleability and useful as a contrasting agent for X-ray examination, etc., by adding a specific amount of a saturated fatty acid alkyl ester to an iodinated oil. CONSTITUTION:The objective contrasting agent composition is produced by compounding an iodinated oil with 5-20vol% 6-14C saturated fatty acid alkyl ester (e.g. methyl caproate). The iodinated oil can be produced by iodinating a fatty acid alkyl ester derived from a liquid vegetable oil such as poppy oil, safflower oil, etc. It contains usually 35-40wt% bonded iodine and is used as a contrasting agent for X-ray examination, however, it is an extremely viscous liquid inconvenient for use. The present contrasting agent composition lowers the viscosity of the iodinated oil to <=15cst at 37 deg.C scarcely deteriorating the radiation-shielding capacity. Accordingly, the handling characteristics of the oil can be improved and a clear image of the details of an organ can be obtained.
Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. "What did you learn?"). Participants are encouraged to keep their own experience in mind during the test trail with the thermode.
Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3–5 event.

Tumor-related hemorrhage was observed in patients treated with SUTENT. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with SUTENT for metastatic RCC, GIST, and metastatic lung cancer. SUTENT is not approved for use in patients with lung cancer.

Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with SUTENT.

Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt SUTENT for Grade 3 or 4 hemorrhagic events until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose.

Discontinue SUTENT in patients without resolution of Grade 3 or 4 hemorrhagic events.
The present invention relates to a medicine for relaxing tendon, activating channel and relieving pain and a preparation method thereof. The medicine comprises parsnip, Radix Rehmanniae Preparata, barbary wolfberry fruit, jujube seed, Peucedanum Decursivum, Indian bread with hostwood, anise, polygonatum, cassia bark, Fructus Jujubae, achyranthes, eucommia bark, pawpaw strip, hemlock parsley, liquorice root, tangerine peel and spirit. The medicines except the sprit are prepared into a share according to the weight ratio, and the medicines are soaked twice by the spirit more than 50 DEG. After the spirit solution is poured out, the medicines are put together. White sugar is added in the medicines to be uniformly to obtain the product. The product has high curative effect and good taste; verified by longtime clinical research, the product has conspicuous curative effect on pain of shoulder, neck, waist and leg caused by various diseases. The product is verified by more than 1000 patients for many years, the total effective rate reaches to 99%.
PROBLEM TO BE SOLVED: To obtain a novel compound, derived from febrifugine, one type of plant alkaloid contained in a crude drug produced from Dichroa febrifugaLour., low in toxicity and very high in antimalarial activity. SOLUTION: This compound is shown by formula I (R1 and R2 are each H or a hydrocarbon; R3 and R4 are each H for the one and hydroxyl or acyloxy for the other, or the like; and R5 is acyl or an ether type protective group which can be selectively eliminated) or its salt, e.g. acetonyl febrifugine shown by formula II. The compound shown by formula I is obtained by the Mannich type cyclization reaction of febrifugine or isofebrifugine shown by formula III with an aldehyde or ketone shown by the formula R1COR2. It is preferable to administer 1 to 600 mg of the compound shown by formula I once or 2 to 4 times a day for an adult. It is recommended that the compound formulated at 0.1 to 50 wt.% in the pharmaceutical preparation.
The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.
Sleep duration - 45 minutes:Children in this arm will be asked to get into bed and to turn their lights out 45 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
OBJECTIVE: The study aimed to compare the clinical efficacy and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) and surgery in treating recurrent cervical high-grade squamous intraepithelial lesions (HSIL) after surgery due to precancerous lesions.
METHODS: A total of 41 patients with recurrent cervical HSIL after surgery for precancerous lesions were studied retrospectively. Patients underwent ALA-PDT or surgery and were followed up at 3, 6, 9 and 12 months and then every six months after that. Clinical data were collected and the efficacy and safety of the two treatment methods were compared.
RESULTS: Of the 41 patients with recurrent cervical HSIL after conization, 15 cases received ALA-PDT and 26 received surgery. At the six-month follow-up, the lesions' complete remission (CR) rate was 93.33 % in ALA-PDT group and 88.46 % in the surgery group. The human papillomavirus (HPV) clearance rates were 66.67 % and 73.08 %, respectively. No significant differences concerning the lesions' CR rate and the HPV clearance rate were observed between the two groups (P>0.05). At the twelve-month follow-up, the HPV clearance rates were 80.00 % and 91.67 %. No significant differences concerning the HPV clearance rate were observed between the two groups (P>0.05). In the surgery group, the HPV clearance rate and the lesions' CR rate were lower in patients over 45 years of age (25.00% vs. 81.82 %, P = 0.031; 50.00% vs. 95.45 %, P = 0.052). During the follow-up, there was no significant difference in the recurrence rate between the two groups (P>0.05). In addition, none of the patients progressed. In women treated with ALA-PDT, there was no vaginal bleeding, and no harmful effects on the cervical organizational structure or functions compared to the surgery group, and two women delivered successfully after ALA-PDT treatment.
CONCLUSIONS: The efficacy of ALA-PDT was similar to that of surgery in treating recurrent cervical HSIL following surgery, with fewer side effects.
Placebo 200g, without any ingredients of inulin fiber. Eat 200g for once, and once a day.
AIM: In frozen-thawed embryo transfer (FET), differences in endometrial preparation methods affect the incidence of perinatal complications. However, the underlying causes are unclear. We aimed to investigate whether serum E2, P4 levels are associated with perinatal complications.
METHODS: This is a retrospective cohort study, involving 306 successful FET pregnancies from 2017 to 2022. Participants were divided into Natural Cycle (NC) and Hormone Replacement Cycle (HRC) group. We compared serum hormone levels, maternal backgrounds, and perinatal outcomes and complications. Furthermore, within the HRC group, serum hormone levels were compared for perinatal complications previously reported to show differences in incidence rates depending on the method of endometrial preparation.
RESULTS: HRC exhibited significantly higher serum E2 levels during the implantation period, but lower P4 levels during ovulation, implantation, and pregnancy test period compared with NC. HRC also had significantly higher rates of postpartum hemorrhage (PPH) and placenta accreta spectrum (PAS). There was no association found between perinatal complications more likely to occur in HRC and serum E2, P4 levels.
CONCLUSIONS: In HRC, there were more occurrences of PPH and PAS. Although serum E2, P4 levels during FET did not correlate with perinatal complications.
Patients will be asked apply a 50 mg/g creme containing imiquimod thrice a week on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
UNLABELLED: Aberrant activation of the NRF2/NFE2L2 transcription factor commonly occurs in head and neck squamous cell carcinomas (HNSCC). Mouse model studies have shown that NRF2 activation alone does not result in cancer. When combined with classic oncogenes and at the right dose, NRF2 activation promotes tumor initiation and progression. Here we deleted the tumor suppressor genes p16INK4A and p53 (referred to as CP mice), which are commonly lost in human HNSCC, in the presence of a constitutively active NRF2E79Q mutant (CPN mice). NRF2E79Q expression in CPN mice resulted in squamous cell hyperplasia or dysplasia with hyperkeratosis in the esophagus, oropharynx, and forestomach. In addition, CPN mice displayed oral cavity squamous cell carcinoma (OSCC); CP mice bearing wild-type NRF2 expression did not develop oral cavity hyperplasia, dysplasia or OSCC. In both CP and CPN mice, we also observed predominantly abdominal sarcomas and carcinomas. Our data show that in the context of p53 and p16 tumor suppressor loss, NRF2 activation serves oncogenic functions to drive OSCC. CPN mice represent a new model for OSCC that closely reflects the genetics of human HNSCC.
SIGNIFICANCE: Human squamous cancers frequently show constitutive NRF2 activation, associated with poorer outcomes and resistance to multiple therapies. Here, we report the first activated NRF2-driven and human-relevant mouse model of squamous cell carcinoma that develops in the background of p16 and p53 loss. The availability of this model will lead to a clearer understanding of how NRF2 contributes to the initiation, progression, and therapeutic response of OSCC.
OBJECTIVE: This study aimed to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD) who were long-term hospitalized.
METHODS: Sixty-four inpatients who met the DSM-IV diagnostic criteria for schizophrenia and TD were randomly assigned to either the active (N=35) or sham (N=29) group. Treatment was given 15 times, with each session lasting for 30 min, and an intensity of 2 mA. The anode was placed on the left dorsolateral prefrontal cortex and the cathode on the right supraorbital region. Primary outcome was measured by the changes in Abnormal Involuntary Movements Scale (AIMS) score. Secondary outcomes were measured using the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS). Adverse effects of tDCS were assessed with an experimenter-administered open-ended questionnaire throughout the experiment.
RESULTS: Of the 64 patients, 52 (81.25%) completed the study. Compared to the sham group, patients in the active group exhibited a significant reduction in both the total AIMS score and the facial-oral subscore (P<0.05). An improvement of at least 30% in total AIMS scores was observed in the active group (14 patients, 50%) compared to the sham group (2 patients, 8.3%) after treatment (P<0.01). There were no between-group differences in the PANSS and SANS total scores. However, there was a significant difference between the two groups in the occurrence of the reported adverse effect of tingling sensation (P<0.05).
CONCLUSIONS: TDCS may be an effective and safe treatment for improving the facial-oral motor symptoms of TD in chronically hospitalized patients with schizophrenia.
SIGNIFICANCE: This study provides a novel perspective for the clinical treatment of patients with TD.
The purpose of this study was to explore the effect of massage therapy on fatigue and sleep quality in patients with heart failure in the intensive care unit. The study design was a randomized control trial and repeated measurements. A convenience sampling was used to recruit heart failure patients with New York Heart Association (NYHA) II-III from the intensive care unit of a regional teaching center. In addition to routine turning, patients in the experimental group received daily back massage intervention for 10 minute, once a day; the control group maintained usual care. The data collection included three time points: baseline, 4th and 7th day after the intervention. Research tools include basic personal data, Piper fatigue scale and Pittsburgh sleep quality scale. Data will be analyzed by descriptive statistics, chi-square test, Pearson product correlation, one-way ANOVA, independent sample t test, repeated measure ANOVA, and generalized estimating equation (GEE)。